The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
In his new role, Shisher will lead Glenmark’s marketing initiatives, focusing on strengthening brand positioning, driving market expansion, and accelerating growth
The decision marks a key step in the centralized EU review process
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
Paves way for CNS cancer test rollout
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
